Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GNOS PV01 + INO 9012

Next Previous
Drug Profile

GNOS PV01 + INO 9012

Alternative Names: GNOS-PV01; Neoantigen vaccine GNOS-PV01; Personalised neoantigen DNA vaccine GNOS-PV01; Personalised Neoantigen-based vaccine GNOS-PV01

Latest Information Update: 24 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geneos Therapeutics
  • Developer Inovio Pharmaceuticals; Washington University School of Medicine
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 24 Jun 2024 Phase I development is ongoing in USA (NCT04015700)
  • 24 Jun 2024 Efficacy data from a phase I trial in Glioblastoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 08 Mar 2024 Geneos Therapeutics completes enrolment in the phase I clinical trials in Glioblastoma (Newly diagnosed) in USA (Parenteral) (NCT04015700)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top